The instruction for medical use
of Terafleks® medicine
the Trade name
of Terafleks®
the International unlicensed name
Is not present
the Dosage form
of the Structure One Capsule Capsule contains
active agents: D-glycosamine hydrochloride of 500 mg, chondroitin sodium sulfate of 400 mg,
excipients: gelatin, stearic acid, magnesium stearate, manganese sulfate.
The description
the Transparent, solid, gelatin capsules 00 of No. in size filled with powder white with insignificant shades or light-beige color with crystalline particles.
Pharmacotherapeutic group
Other drugs for treatment of diseases of the musculoskeletal system.
The ATX M09AX code
the Pharmacological
Chondroitin Pharmacokinetics properties sulfate – after oral introduction of a single therapeutic dose the maximum levels in blood plasma are reached within 3-4 hours, in synovial fluid – within 4-5 hours. The bioavailability is 13%. It is allocated mainly through kidneys during the 24th sentry of the period.
A glycosamine the hydrochloride – after intake of 90% is soaked up in intestines. More than 25% come from plasma to cartilaginous tissue and synovial articulate fluid. In a liver a part of drug is metabolized to urea, carbon dioxide and water. The bioavailability of a glycosamine is 25%. The highest concentrations of a glycosamine are found in a liver, kidneys and cartilaginous tissue. About 30% of the entered dose remain in bone and muscle tissue during the long period. In not changed type of a glycosamine the hydrochloride is removed generally by kidneys. Elimination half-life makes 68 hours.
The Chondroitin pharmacodynamics sulfate is the high-molecular mucopolysaccharide participating in construction and restoration of cartilaginous tissue. Reduces activity of the enzymes destroying a joint cartilage and stimulates its regeneration (biosynthesis of glucosaminoglycans). At early stages of inflammatory process of chondroitin sulfate slows down destruction of cartilaginous tissue. Has anti-inflammatory effect, promotes decrease in intensity of a pain syndrome, improvement of function of joints. A glycosamine the hydrochloride has hondroprotektorny and osteotropny properties, reduces deficiency of glucosaminoglycans in an organism, takes part in biosynthesis of proteoglycans and hyaluronic acid, normalizes adjournment of calcium in a bone tissue. Having a high tropnost to cartilaginous tissue, a glycosamine the hydrochloride initiates process of fixing of sulfur at synthesis of chondroitinsulphuric acid. A glycosamine the hydrochloride oppresses formation of the superoxidic radicals and enzymes damaging cartilaginous tissue (collagenases and phospholipases), prevents the destroying action of glucocorticoids, non-steroidal anti-inflammatory drugs on chondrocytes and disturbance of biosynthesis of glucosaminoglycans.
The combination of chondroitin of sulfate and a glycosamine of a hydrochloride provides more significant and more long clinical effect.
Indications
– an osteoarthrosis
– osteoporosis
– a humeroscapular periarthritis
– osteochondrosis, degenerative dystrophic diseases of a backbone
– a spondylosis
– the patella chondromalacia
– changes (for acceleration of formation of a bone callosity)
Is recommended to children 12 years, to adults, elderly people as a part of complex treatment of diseases of the musculoskeletal system, the posttraumatic and other states which are followed by degenerative dystrophic changes of tissues of articulate cartilage are more senior.
The route of administration and doses
to Adults and children are more senior than 12 years the first three weeks appoint on 1 capsule 3 times a day after a meal, in the next days – on 1 capsule 2 times a day. The minimum course of reception makes 2 months. Courses of treatment are repeated with intervals in 3 months or in coordination with the doctor.
Side effects
– nausea
– a stomach ache
– intestines swelling
– diarrhea or a constipation
– allergic reactions
of the Contraindication
– the increased individual sensitivity to any of drug components (allergic reactions)
– phenylketonuria
– pregnancy, the lactation period
– children's age up to 12 years
Medicinal interactions
Drug improves digestion of tetracyclines and reduces effect of penicillin and chloramphenicol.
Терафлекс® strengthens action of antiagregant, fibrinolitik and also coumarinic anticoagulants (for example, warfarin) with which at a concomitant use indicators of a koagulogramma (MNO) can change and raise risk of bleedings.
Against the background of reception of Terafleksa® the need for non-steroidal anti-inflammatory drugs decreases.
Special indications
of Feature of influence on ability to run motor transport and other mechanisms
the Overdose does not influence
So far cases of overdose are not described. At overdose strengthening of side effects is possible.
Treatment: gastric lavage and performing symptomatic therapy is recommended.
A form of release and packing
On 30, 60, 120 capsules in a bottle from polyethylene of high density with the screwing-up cover from white polypropylene. The neck of a bottle is sealed up a signature membrane from the combined material: aluminum foil / the paper laminated by polyethylene over a cover - a protective film from transparent polyethylene. The bottle together with the instruction for medical use in the state and Russian languages is placed in a pack from cardboard.
To Store storage conditions at a temperature not above 25 °C.
To store out of children's reach!
3 years
not to use a period of storage after the expiration date specified on packing.
Prescription status
Without prescription
the Name and the country
of the manufacturing organization Contract Pharmakal Corporation, USA Naimenovaniye and the country of the owner of the registration certificate
of Bayer Konsyyumer Ker AG, Switzerland
the Name and the country
of the organization packer Contract Pharmakal Corporation, USA Adres of the organization accepting in the territory of the Republic of Kazakhstan claims from consumers on quality of a product (goods):
TOO Bayer KAZ Timiryazev St., 42, business center Expo-City, peahens. 15
050057 Almaty, Republic of Kazakhstan
Ph.: +7 727 258 80 40 (148)
Fax: +7 727 244 70 01
e-mail: kz.claims@bayer.com
of Terafleks® medicine
the Trade name
of Terafleks®
the International unlicensed name
Is not present
the Dosage form
of the Structure One Capsule Capsule contains
active agents: D-glycosamine hydrochloride of 500 mg, chondroitin sodium sulfate of 400 mg,
excipients: gelatin, stearic acid, magnesium stearate, manganese sulfate.
The description
the Transparent, solid, gelatin capsules 00 of No. in size filled with powder white with insignificant shades or light-beige color with crystalline particles.
Pharmacotherapeutic group
Other drugs for treatment of diseases of the musculoskeletal system.
The ATX M09AX code
the Pharmacological
Chondroitin Pharmacokinetics properties sulfate – after oral introduction of a single therapeutic dose the maximum levels in blood plasma are reached within 3-4 hours, in synovial fluid – within 4-5 hours. The bioavailability is 13%. It is allocated mainly through kidneys during the 24th sentry of the period.
A glycosamine the hydrochloride – after intake of 90% is soaked up in intestines. More than 25% come from plasma to cartilaginous tissue and synovial articulate fluid. In a liver a part of drug is metabolized to urea, carbon dioxide and water. The bioavailability of a glycosamine is 25%. The highest concentrations of a glycosamine are found in a liver, kidneys and cartilaginous tissue. About 30% of the entered dose remain in bone and muscle tissue during the long period. In not changed type of a glycosamine the hydrochloride is removed generally by kidneys. Elimination half-life makes 68 hours.
The Chondroitin pharmacodynamics sulfate is the high-molecular mucopolysaccharide participating in construction and restoration of cartilaginous tissue. Reduces activity of the enzymes destroying a joint cartilage and stimulates its regeneration (biosynthesis of glucosaminoglycans). At early stages of inflammatory process of chondroitin sulfate slows down destruction of cartilaginous tissue. Has anti-inflammatory effect, promotes decrease in intensity of a pain syndrome, improvement of function of joints. A glycosamine the hydrochloride has hondroprotektorny and osteotropny properties, reduces deficiency of glucosaminoglycans in an organism, takes part in biosynthesis of proteoglycans and hyaluronic acid, normalizes adjournment of calcium in a bone tissue. Having a high tropnost to cartilaginous tissue, a glycosamine the hydrochloride initiates process of fixing of sulfur at synthesis of chondroitinsulphuric acid. A glycosamine the hydrochloride oppresses formation of the superoxidic radicals and enzymes damaging cartilaginous tissue (collagenases and phospholipases), prevents the destroying action of glucocorticoids, non-steroidal anti-inflammatory drugs on chondrocytes and disturbance of biosynthesis of glucosaminoglycans.
The combination of chondroitin of sulfate and a glycosamine of a hydrochloride provides more significant and more long clinical effect.
Indications
– an osteoarthrosis
– osteoporosis
– a humeroscapular periarthritis
– osteochondrosis, degenerative dystrophic diseases of a backbone
– a spondylosis
– the patella chondromalacia
– changes (for acceleration of formation of a bone callosity)
Is recommended to children 12 years, to adults, elderly people as a part of complex treatment of diseases of the musculoskeletal system, the posttraumatic and other states which are followed by degenerative dystrophic changes of tissues of articulate cartilage are more senior.
The route of administration and doses
to Adults and children are more senior than 12 years the first three weeks appoint on 1 capsule 3 times a day after a meal, in the next days – on 1 capsule 2 times a day. The minimum course of reception makes 2 months. Courses of treatment are repeated with intervals in 3 months or in coordination with the doctor.
Side effects
– nausea
– a stomach ache
– intestines swelling
– diarrhea or a constipation
– allergic reactions
of the Contraindication
– the increased individual sensitivity to any of drug components (allergic reactions)
– phenylketonuria
– pregnancy, the lactation period
– children's age up to 12 years
Medicinal interactions
Drug improves digestion of tetracyclines and reduces effect of penicillin and chloramphenicol.
Терафлекс® strengthens action of antiagregant, fibrinolitik and also coumarinic anticoagulants (for example, warfarin) with which at a concomitant use indicators of a koagulogramma (MNO) can change and raise risk of bleedings.
Against the background of reception of Terafleksa® the need for non-steroidal anti-inflammatory drugs decreases.
Special indications
of Feature of influence on ability to run motor transport and other mechanisms
the Overdose does not influence
So far cases of overdose are not described. At overdose strengthening of side effects is possible.
Treatment: gastric lavage and performing symptomatic therapy is recommended.
A form of release and packing
On 30, 60, 120 capsules in a bottle from polyethylene of high density with the screwing-up cover from white polypropylene. The neck of a bottle is sealed up a signature membrane from the combined material: aluminum foil / the paper laminated by polyethylene over a cover - a protective film from transparent polyethylene. The bottle together with the instruction for medical use in the state and Russian languages is placed in a pack from cardboard.
To Store storage conditions at a temperature not above 25 °C.
To store out of children's reach!
3 years
not to use a period of storage after the expiration date specified on packing.
Prescription status
Without prescription
the Name and the country
of the manufacturing organization Contract Pharmakal Corporation, USA Naimenovaniye and the country of the owner of the registration certificate
of Bayer Konsyyumer Ker AG, Switzerland
the Name and the country
of the organization packer Contract Pharmakal Corporation, USA Adres of the organization accepting in the territory of the Republic of Kazakhstan claims from consumers on quality of a product (goods):
TOO Bayer KAZ Timiryazev St., 42, business center Expo-City, peahens. 15
050057 Almaty, Republic of Kazakhstan
Ph.: +7 727 258 80 40 (148)
Fax: +7 727 244 70 01
e-mail: kz.claims@bayer.com
Related Products
Recently Viewed
